跳至主要内容
临床试验/NCT04732364
NCT04732364Unknown2 期

Analgesic Efficacy of Magnesium Sulphate as an Adjuvant to Levo-bupivacine in Ultrasound Guided Erector Spinae Plan Block for Modified Radical Mastectomy

South Egypt Cancer Institute2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2018年4月30日最近更新:
适应症

试验速览

阶段
2 期
发起方
入组人数
60
试验地点
2
主要终点
analgesia requirement

研究概览

简要总结

To compare the analgesic efficacy of dexmedetomidine and magnesium sulphate as adjuvants to levobupivacaine in erector spinae plane block in modified radical mastectomy surgery for acute and chronic pain management.

详细描述

3 groups.

Group (C) / (I):20 patient (control group) :

Patients will receive 20 ml 0.25% levobupivacaine into the interfascial plane below erector spinae muscle at level of T5.

Group (D)/ (II) :20 patient (Dexmetonidine group) :

Patient will receive 20ml 0.25% levobupivacaineas above + 1μ/kg dexmedetomidine.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
25 Years 至 70 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • female patient
  • American society of anesthesiologists (ASA) I and II physical status
  • age from 25 to 70 years old
  • scheduled for either left or right modified radical mastectomy (MRM).

排除标准

  • infection of the skin at or near site of needle puncture
  • coagulopathy
  • drug hypersensitivity or allergy to the studied drugs
  • central or peripheral neuropathy
  • significant organ dysfunction cardiac dysrrhythmias
  • obesity (BMI>35kg/m2)
  • recently use analgesic drugs

结局指标

主要结局

analgesia requirement

时间窗: 24 hours

first request for analgesia and total analgesia requirements

次要结局

  • chronic pain assessment(6 months)

研究者

发起方
South Egypt Cancer Institute
申办方类型
Other
责任方
Principal Investigator
主要研究者

Peter Rafaat Edward Iskander

principal investigator

South Egypt Cancer Institute

研究点 (2)

Loading locations...

相似试验